USA flag logo/image

An Official Website of the United States Government

Live Attenuated Salmonella Vaccine Against Campylobacter

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75944
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
AI065039
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AVANT IMMUNOTHERAPEUTICS, INC.
AVANT IMMUNOTHERAPEUTICS, INC. 119 4TH AVE NEEDHAM, MA 02494 0272
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Live Attenuated Salmonella Vaccine Against Campylobacter
Agency: HHS
Contract: 1R43AI065039-01
Award Amount: $130,810.00
 

Abstract:

DESCRIPTION (provided by applicant): The bacterium, Campylobacter jejuni, is a major cause of diarrheal illness in both the developed and developing world. It is estimated that Campylobacter may affect as many as 400 million people and cause 14 percent of all diarrheal cases worldwide. There is currently no human vaccine for the prevention of Campylobacter disease or colonization. Live, attenuated Salmonella typhi is the most frequently studied vector for delivering foreign (vaccine) antigens in humans. More current thinking, however, suggests that attenuated vectors based on S. typhimurium may more effectively focus the induction of gastrointestinal immune responses to optimize against mucosal infection such as Campylobacter. Attenuated S. typhimurium vaccines elicit the production of immune responses in the intestinal tract inducing both systemic and mucosal immunity. Our goal is to construct live, attenuated strains of S. typhimurium that express C. jejuni genes that encode antigens known for their role in adherence, invasion or colonization, and to evaluate these strains for the capacity to induce systemic and mucosal immune responses that protect against Campylobacter infection. The accomplishment of these goals will provide new Campylobacter vaccines with the potential to rapidly confer protective immunity by oral immunization in humans.

Principal Investigator:

Kenneth L. Roland
3149839050
KROLAND@AVANTIMMUNE.COM

Business Contact:

Una Ryan
7814330771
uryan@avantimmune.com
Small Business Information at Submission:

Avant Immunotherapeutics, Inc.
Avant Immunotherapeutics, Inc. 119 4Th Ave Needham, MA 02494

EIN/Tax ID: 133191702
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No